SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: Invest2Ride who wrote (454)10/8/1998 5:48:00 PM
From: James Perry  Read Replies (1) | Respond to of 1025
 
Yeah, but sale of supplies is an even greater and more sustaining force. It is most important whether they move free of royalties.



To: Invest2Ride who wrote (454)12/2/1998 6:38:00 PM
From: James Perry  Read Replies (1) | Respond to of 1025
 
A payoff on the use of a single patent, yes, but not the sale of the entire patent. The patent covers the ECLM process, and Roche has a license which covers a substantial market. But it is very far from the whole pie. And yes, the tests are very important, also.



To: Invest2Ride who wrote (454)12/2/1998 6:38:00 PM
From: James Perry  Respond to of 1025
 
A payoff on the use of a single patent, yes, but not the sale of the entire patent. The patent covers the ECLM process, and Roche has a license which covers a substantial market. But it is very far from the whole pie. And yes, the tests are very important, also.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News